| Efficacy and Safety of Inhibitors of the Proximal Pathway of the Complement System in Paroxysmal Nocturnal Hemoglobinuria: A Meta-analysis of Randomized Controlled Trials |
|
American Journal of Therapeutics |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions |
|
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
| Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria |
|
Expert Opinion on Pharmacotherapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria |
|
Expert Opinion on Pharmacotherapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Massive hemolysis in paroxysmal nocturnal hemoglobinuria after switching from proximal complement inhibitor to anti-C5 therapy: A lesson not to be forgotten |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Family reflections: pediatric aplastic anemia research; a parent perspective |
|
Pediatric Research |
Aplastic Anemia, Pediatric |
| Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria |
|
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Myelodysplastic Syndromes Treatment (PDQ®): Patient Version |
|
PDQ Cancer Information Summaries |
Myelodysplastic Syndromes (MDS) |
| Advances in the management of higher-risk myelodysplastic syndromes: future prospects |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial |
|
The Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
